Literature DB >> 6158984

Hb F synthesis in sickle cell anaemia: a comparison of Saudi Arab cases with those of African origin.

W G Wood, M E Pembrey, G R Serjeant, R P Perrine, D J Weatherall.   

Abstract

Fetal haemoglobin (Hb F) synthesis has been studied in 22 cases of sickle cell anemia (SS) from Saudi Arabia and compared with an equal number of cases of African origin. Among the Saudi Arabs gamma chain synthesis ranged from 4.0% to 19.9% of the total non-alpha chain synthesis (mean 8.1%) while the corresponding range for the Negro cases was < 0.3% to 4.6% (mean 1.7%). In both groups the peripheral blood Hb F level was on average 3--4 times higher than the proportion synthesized, indicating that the selective survival of Hb F containing cells (F cells) was an important factor in determining the final Hb F levels. Among the Saudi Arab cases there was a significant negative correlation between the degree of F cell enrichment and either the Hb F level of the percentage gamma chain synthesis. No such correlation was observed among the Negro cases. A high proportion of the cases in both groups were carriers of alpha thalassaemia in addition to SS, but no effect of alpha thalassaemia on Hb F production was observed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158984     DOI: 10.1111/j.1365-2141.1980.tb07163.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Regulation of fetal hemoglobin synthesis in sickle cell anemia.

Authors:  D G Nathan
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

2.  Therapeutic manipulation of globin gene expression in the hemoglobinopathies.

Authors:  C S Johnson
Journal:  J Natl Med Assoc       Date:  1986-07       Impact factor: 1.798

3.  Evaluation of haematological findings in 50 Bahraini patients with sickle cell disease and in some of their parents.

Authors:  M A Buhazza; A B Bikhazi; F P Khouri
Journal:  J Med Genet       Date:  1985-08       Impact factor: 6.318

4.  A novel TMPRSS3 missense mutation in a DFNB8/10 family prevents proteolytic activation of the protein.

Authors:  Marie Wattenhofer; Nilüfer Sahin-Calapoglu; Ditte Andreasen; Ersan Kalay; Refik Caylan; Bastien Braillard; Nicole Fowler-Jaeger; Alexandre Reymond; Bernard C Rossier; Ahmet Karaguzel; Stylianos E Antonarakis
Journal:  Hum Genet       Date:  2005-07-14       Impact factor: 4.132

5.  Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.

Authors:  G F Atweh; M Sutton; I Nassif; V Boosalis; G J Dover; S Wallenstein; E Wright; L McMahon; G Stamatoyannopoulos; D V Faller; S P Perrine
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

Review 6.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

Review 7.  Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies.

Authors:  S P Perrine; D V Faller
Journal:  Experientia       Date:  1993-02-15

8.  Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells.

Authors:  Himanshu Bhatia; Jennifer L Hallock; Amrita Dutta; Shay Karkashon; Lauren S Sterner; Toru Miyazaki; Ann Dean; Jane A Little
Journal:  Blood       Date:  2009-04-20       Impact factor: 22.113

9.  Recombinant human hemoglobins designed for gene therapy of sickle cell disease.

Authors:  S L McCune; M P Reilly; M J Chomo; T Asakura; T M Townes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.